FIELD: medicine.
SUBSTANCE: invention relates to experimental medicine and can be used as model for studying pathogenesis of various forms of pulmonary embolism and for pre-clinical tests of potential antiplatelet agents, anticoagulants and thrombolytics. To model pulmonary embolism blood flow in inferior vena cava of rat is blocked. To cause development of embolism of small branches of pulmonary artery at the level of segmental arteries occlusion is preserved for 1.5-3.0 hours. To form embolism at the level of lobar arteries vein occlusion is preserved for 3.1-6.0 hours with the following opening of blood flow.
EFFECT: method provides increase of modelling accuracy due to formation of pathogenetic model of pulmonary embolism from the level of small branches to lobar arteries of pulmonary artery with development of massive embolism.
16 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR TREATMENT AND PREVENTION OF THROMBOSIS | 2017 |
|
RU2662308C1 |
| METHOD FOR MODELING PULMONARY ARTERY THROMBOSIS IN CONDITIONS OF VENOUS THROMBOSIS | 2021 |
|
RU2770355C1 |
| METHOD OF MODELING HEMOSTASIS SYSTEM DISORDERS | 2019 |
|
RU2714597C1 |
| EARLY DIAGNOSTIC TECHNIQUE FOR SEGMENTAL AND SUB-SEGMENTAL; PULMONARY THROMBOEMBOLISM | 2013 |
|
RU2532882C1 |
| METHOD FOR QUANTIFYING THE MASSIVENESS OF PULMONARY EMBOLISM | 2021 |
|
RU2767140C1 |
| MEDICATION FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2014 |
|
RU2555335C9 |
| METHOD OF MODELING CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION | 2018 |
|
RU2675353C1 |
| MEDICINAL PRODUCT WITH ANTICOAGULANT (INHIBITOR OF FACTOR IIA), ANTITHROMBOTIC, ANTI-INFLAMMATORY ACTIVITIES AND CONTAINING 5,7-DI(THIOPHEN-2-IL)-4,5-DIHYDRO-[1,2,4]TRIAZOLO[1,5-a ]PYRIMIDINE | 2022 |
|
RU2798587C1 |
| METHOD FOR SURGICAL TREATMENT OF ACUTE PULMONARY EMBOLISM OF HIGH AND MEDIUM-HIGH RISK | 2021 |
|
RU2789686C1 |
| X-RAY DIAGNOSTIC TECHNIQUE FOR THROMBOEMBOLIA OF PULMONARY ARTERIES | 2013 |
|
RU2541270C1 |
